Industry Research Reports
Home > Reports > Service & Software > Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Industry: Service & Software
Published Date: 2025-09-06
Pages: 106 Pages
Report ld: 4956022
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
The North America Oligonucleotide Drug CDMO Services market size was US$ million in 2024, while Europe was US$ million. The proportion of the North America was % in 2024, while Europe percentage was %, and it is predicted that Europe share will reach % in 2031, trailing a CAGR of % through the analysis period.
The global key players of Oligonucleotide Drug CDMO Services include Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma, Cytiva, TriLink BioTechnologies, etc. In 2024, the global top five players occupied for a share approximately % in terms of revenue.
In North America, in terms of revenue, in 2024, the top three players hold a share about %, while in Europe, top three players hold a share nearly %.
The global Oligonucleotide Drug CDMO Services market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2020-2031.
MARKET SEGMENTATION
By Company
- Bachem
- WuXi TIDES
- Ajinomoto Co
- Waters
- AGC Biologics
- Merck KGaA
- EUROAPI
- CordenPharma
- Cytiva
- TriLink BioTechnologies
- Medicilon
- General Biol
- BioSpring
- Bio-Synthesis Inc
- Aurisco
- Suzhou Olipharma Co.,Ltd
- Porton
- RIBOPharm
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- API
- Preparation
Segment by Application
- SME Pharmaceutical Company
- Large Pharmaceutical Company
CHAPTER OUTLINE
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Oligonucleotide Drug CDMO Services market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Preparation in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Large Pharmaceutical Company in India).
Chapter 6: Regional revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Oligonucleotide Drug CDMO Services value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 API
1.2.3 Preparation
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 SME Pharmaceutical Company
1.3.3 Large Pharmaceutical Company
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Drug CDMO Services Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Oligonucleotide Drug CDMO Services Revenue Market Share by Region (2020-2025)
2.4 Global Oligonucleotide Drug CDMO Services Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Oligonucleotide Drug CDMO Services Market Size and Prospective (2020-2031)
2.5.2 Europe Oligonucleotide Drug CDMO Services Market Size and Prospective (2020-2031)
2.5.3 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size and Prospective (2020-2031)
2.5.4 Latin America Oligonucleotide Drug CDMO Services Market Size and Prospective (2020-2031)
2.5.5 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Type (2020-2025)
3.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Type (2026-2031)
3.3 Different Types Oligonucleotide Drug CDMO Services Representative Players
4 Breakdown Data by Application
4.1 Global Oligonucleotide Drug CDMO Services Historic Market Size by Application (2020-2025)
4.2 Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Oligonucleotide Drug CDMO Services Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Oligonucleotide Drug CDMO Services Players by Revenue (2020-2025)
5.1.2 Global Oligonucleotide Drug CDMO Services Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Oligonucleotide Drug CDMO Services Revenue
5.4 Global Oligonucleotide Drug CDMO Services Market Concentration Analysis
5.4.1 Global Oligonucleotide Drug CDMO Services Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Drug CDMO Services Revenue in 2024
5.5 Global Key Players of Oligonucleotide Drug CDMO Services Head office and Area Served
5.6 Global Key Players of Oligonucleotide Drug CDMO Services, Product and Application
5.7 Global Key Players of Oligonucleotide Drug CDMO Services, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025)
6.1.2.2 North America Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025)
6.1.3.2 North America Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025)
6.2.2.2 Europe Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025)
6.2.3.2 Europe Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 Asia-Pacific Market: Players, Segments and Downstream
6.3.1 Asia-Pacific Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025)
6.3.2.2 Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025)
6.3.3.2 Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
6.3.4 Asia-Pacific Market Trend and Opportunities
6.4 Latin America Market: Players, Segments and Downstream
6.4.1 Latin America Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025)
6.4.2.2 Latin America Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025)
6.4.3.2 Latin America Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
6.4.4 Latin America Market Trend and Opportunities
6.5 Middle East & Africa Market: Players, Segments and Downstream
6.5.1 Middle East & Africa Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025)
6.5.2.2 Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025)
6.5.3.2 Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
6.5.4 Middle East & Africa Market Trend and Opportunities
7 Key Players Profiles
7.1 Bachem
7.1.1 Bachem Company Details
7.1.2 Bachem Business Overview
7.1.3 Bachem Oligonucleotide Drug CDMO Services Introduction
7.1.4 Bachem Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.1.5 Bachem Recent Development
7.2 WuXi TIDES
7.2.1 WuXi TIDES Company Details
7.2.2 WuXi TIDES Business Overview
7.2.3 WuXi TIDES Oligonucleotide Drug CDMO Services Introduction
7.2.4 WuXi TIDES Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.2.5 WuXi TIDES Recent Development
7.3 Ajinomoto Co
7.3.1 Ajinomoto Co Company Details
7.3.2 Ajinomoto Co Business Overview
7.3.3 Ajinomoto Co Oligonucleotide Drug CDMO Services Introduction
7.3.4 Ajinomoto Co Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.3.5 Ajinomoto Co Recent Development
7.4 Waters
7.4.1 Waters Company Details
7.4.2 Waters Business Overview
7.4.3 Waters Oligonucleotide Drug CDMO Services Introduction
7.4.4 Waters Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.4.5 Waters Recent Development
7.5 AGC Biologics
7.5.1 AGC Biologics Company Details
7.5.2 AGC Biologics Business Overview
7.5.3 AGC Biologics Oligonucleotide Drug CDMO Services Introduction
7.5.4 AGC Biologics Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.5.5 AGC Biologics Recent Development
7.6 Merck KGaA
7.6.1 Merck KGaA Company Details
7.6.2 Merck KGaA Business Overview
7.6.3 Merck KGaA Oligonucleotide Drug CDMO Services Introduction
7.6.4 Merck KGaA Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.6.5 Merck KGaA Recent Development
7.7 EUROAPI
7.7.1 EUROAPI Company Details
7.7.2 EUROAPI Business Overview
7.7.3 EUROAPI Oligonucleotide Drug CDMO Services Introduction
7.7.4 EUROAPI Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.7.5 EUROAPI Recent Development
7.8 CordenPharma
7.8.1 CordenPharma Company Details
7.8.2 CordenPharma Business Overview
7.8.3 CordenPharma Oligonucleotide Drug CDMO Services Introduction
7.8.4 CordenPharma Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.8.5 CordenPharma Recent Development
7.9 Cytiva
7.9.1 Cytiva Company Details
7.9.2 Cytiva Business Overview
7.9.3 Cytiva Oligonucleotide Drug CDMO Services Introduction
7.9.4 Cytiva Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.9.5 Cytiva Recent Development
7.10 TriLink BioTechnologies
7.10.1 TriLink BioTechnologies Company Details
7.10.2 TriLink BioTechnologies Business Overview
7.10.3 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Introduction
7.10.4 TriLink BioTechnologies Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.10.5 TriLink BioTechnologies Recent Development
7.11 Medicilon
7.11.1 Medicilon Company Details
7.11.2 Medicilon Business Overview
7.11.3 Medicilon Oligonucleotide Drug CDMO Services Introduction
7.11.4 Medicilon Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.11.5 Medicilon Recent Development
7.12 General Biol
7.12.1 General Biol Company Details
7.12.2 General Biol Business Overview
7.12.3 General Biol Oligonucleotide Drug CDMO Services Introduction
7.12.4 General Biol Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.12.5 General Biol Recent Development
7.13 BioSpring
7.13.1 BioSpring Company Details
7.13.2 BioSpring Business Overview
7.13.3 BioSpring Oligonucleotide Drug CDMO Services Introduction
7.13.4 BioSpring Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.13.5 BioSpring Recent Development
7.14 Bio-Synthesis Inc
7.14.1 Bio-Synthesis Inc Company Details
7.14.2 Bio-Synthesis Inc Business Overview
7.14.3 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Introduction
7.14.4 Bio-Synthesis Inc Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.14.5 Bio-Synthesis Inc Recent Development
7.15 Aurisco
7.15.1 Aurisco Company Details
7.15.2 Aurisco Business Overview
7.15.3 Aurisco Oligonucleotide Drug CDMO Services Introduction
7.15.4 Aurisco Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.15.5 Aurisco Recent Development
7.16 Suzhou Olipharma Co.,Ltd
7.16.1 Suzhou Olipharma Co.,Ltd Company Details
7.16.2 Suzhou Olipharma Co.,Ltd Business Overview
7.16.3 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Introduction
7.16.4 Suzhou Olipharma Co.,Ltd Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.16.5 Suzhou Olipharma Co.,Ltd Recent Development
7.17 Porton
7.17.1 Porton Company Details
7.17.2 Porton Business Overview
7.17.3 Porton Oligonucleotide Drug CDMO Services Introduction
7.17.4 Porton Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.17.5 Porton Recent Development
7.18 RIBOPharm
7.18.1 RIBOPharm Company Details
7.18.2 RIBOPharm Business Overview
7.18.3 RIBOPharm Oligonucleotide Drug CDMO Services Introduction
7.18.4 RIBOPharm Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025)
7.18.5 RIBOPharm Recent Development
8 Oligonucleotide Drug CDMO Services Market Dynamics
8.1 Oligonucleotide Drug CDMO Services Industry Trends
8.2 Oligonucleotide Drug CDMO Services Market Drivers
8.3 Oligonucleotide Drug CDMO Services Market Challenges
8.4 Oligonucleotide Drug CDMO Services Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Oligonucleotide Drug CDMO Services Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Oligonucleotide Drug CDMO Services Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Oligonucleotide Drug CDMO Services Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Oligonucleotide Drug CDMO Services Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Oligonucleotide Drug CDMO Services Revenue Share by Region (2020-2025)
Table 6. Global Oligonucleotide Drug CDMO Services Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Oligonucleotide Drug CDMO Services Revenue Share Forecast by Region (2026-2031)
Table 8. Global Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Type (2020-2025)
Table 10. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Application (2020-2025)
Table 15. Global Oligonucleotide Drug CDMO Services Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Oligonucleotide Drug CDMO Services Application
Table 18. Global Oligonucleotide Drug CDMO Services Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Oligonucleotide Drug CDMO Services Market Share by Players (2020-2025)
Table 20. Global Top Oligonucleotide Drug CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drug CDMO Services as of 2024)
Table 21. Ranking of Global Top Oligonucleotide Drug CDMO Services Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Oligonucleotide Drug CDMO Services Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Oligonucleotide Drug CDMO Services, Headquarters and Area Served
Table 24. Global Key Players of Oligonucleotide Drug CDMO Services, Product and Application
Table 25. Global Key Players of Oligonucleotide Drug CDMO Services, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Oligonucleotide Drug CDMO Services Revenue Market Share by Company (2020-2025)
Table 29. North America Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Oligonucleotide Drug CDMO Services Revenue Market Share by Company (2020-2025)
Table 33. Europe Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025) & (US$ Million)
Table 35. Asia-Pacific Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025) & (US$ Million)
Table 36. Asia-Pacific Oligonucleotide Drug CDMO Services Revenue Market Share by Company (2020-2025)
Table 37. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025) & (US$ Million)
Table 38. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025) & (US$ Million)
Table 39. Latin America Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025) & (US$ Million)
Table 40. Latin America Oligonucleotide Drug CDMO Services Revenue Market Share by Company (2020-2025)
Table 41. Latin America Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025) & (US$ Million)
Table 42. Latin America Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025) & (US$ Million)
Table 43. Middle East & Africa Oligonucleotide Drug CDMO Services Revenue by Company (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Oligonucleotide Drug CDMO Services Revenue Market Share by Company (2020-2025)
Table 45. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Type (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Application (2020-2025) & (US$ Million)
Table 47. Bachem Company Details
Table 48. Bachem Business Overview
Table 49. Bachem Oligonucleotide Drug CDMO Services Product
Table 50. Bachem Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 51. Bachem Recent Development
Table 52. WuXi TIDES Company Details
Table 53. WuXi TIDES Business Overview
Table 54. WuXi TIDES Oligonucleotide Drug CDMO Services Product
Table 55. WuXi TIDES Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 56. WuXi TIDES Recent Development
Table 57. Ajinomoto Co Company Details
Table 58. Ajinomoto Co Business Overview
Table 59. Ajinomoto Co Oligonucleotide Drug CDMO Services Product
Table 60. Ajinomoto Co Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 61. Ajinomoto Co Recent Development
Table 62. Waters Company Details
Table 63. Waters Business Overview
Table 64. Waters Oligonucleotide Drug CDMO Services Product
Table 65. Waters Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 66. Waters Recent Development
Table 67. AGC Biologics Company Details
Table 68. AGC Biologics Business Overview
Table 69. AGC Biologics Oligonucleotide Drug CDMO Services Product
Table 70. AGC Biologics Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 71. AGC Biologics Recent Development
Table 72. Merck KGaA Company Details
Table 73. Merck KGaA Business Overview
Table 74. Merck KGaA Oligonucleotide Drug CDMO Services Product
Table 75. Merck KGaA Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 76. Merck KGaA Recent Development
Table 77. EUROAPI Company Details
Table 78. EUROAPI Business Overview
Table 79. EUROAPI Oligonucleotide Drug CDMO Services Product
Table 80. EUROAPI Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 81. EUROAPI Recent Development
Table 82. CordenPharma Company Details
Table 83. CordenPharma Business Overview
Table 84. CordenPharma Oligonucleotide Drug CDMO Services Product
Table 85. CordenPharma Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 86. CordenPharma Recent Development
Table 87. Cytiva Company Details
Table 88. Cytiva Business Overview
Table 89. Cytiva Oligonucleotide Drug CDMO Services Product
Table 90. Cytiva Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 91. Cytiva Recent Development
Table 92. TriLink BioTechnologies Company Details
Table 93. TriLink BioTechnologies Business Overview
Table 94. TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product
Table 95. TriLink BioTechnologies Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 96. TriLink BioTechnologies Recent Development
Table 97. Medicilon Company Details
Table 98. Medicilon Business Overview
Table 99. Medicilon Oligonucleotide Drug CDMO Services Product
Table 100. Medicilon Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 101. Medicilon Recent Development
Table 102. General Biol Company Details
Table 103. General Biol Business Overview
Table 104. General Biol Oligonucleotide Drug CDMO Services Product
Table 105. General Biol Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 106. General Biol Recent Development
Table 107. BioSpring Company Details
Table 108. BioSpring Business Overview
Table 109. BioSpring Oligonucleotide Drug CDMO Services Product
Table 110. BioSpring Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 111. BioSpring Recent Development
Table 112. Bio-Synthesis Inc Company Details
Table 113. Bio-Synthesis Inc Business Overview
Table 114. Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product
Table 115. Bio-Synthesis Inc Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 116. Bio-Synthesis Inc Recent Development
Table 117. Aurisco Company Details
Table 118. Aurisco Business Overview
Table 119. Aurisco Oligonucleotide Drug CDMO Services Product
Table 120. Aurisco Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 121. Aurisco Recent Development
Table 122. Suzhou Olipharma Co.,Ltd Company Details
Table 123. Suzhou Olipharma Co.,Ltd Business Overview
Table 124. Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product
Table 125. Suzhou Olipharma Co.,Ltd Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 126. Suzhou Olipharma Co.,Ltd Recent Development
Table 127. Porton Company Details
Table 128. Porton Business Overview
Table 129. Porton Oligonucleotide Drug CDMO Services Product
Table 130. Porton Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 131. Porton Recent Development
Table 132. RIBOPharm Company Details
Table 133. RIBOPharm Business Overview
Table 134. RIBOPharm Oligonucleotide Drug CDMO Services Product
Table 135. RIBOPharm Revenue in Oligonucleotide Drug CDMO Services Business (2020-2025) & (US$ Million)
Table 136. RIBOPharm Recent Development
Table 137. Oligonucleotide Drug CDMO Services Market Trends
Table 138. Oligonucleotide Drug CDMO Services Market Drivers
Table 139. Oligonucleotide Drug CDMO Services Market Challenges
Table 140. Oligonucleotide Drug CDMO Services Market Restraints
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources
List of Figures
Figure 1. Oligonucleotide Drug CDMO Services Product Picture
Figure 2. Global Oligonucleotide Drug CDMO Services Market Share by Type: 2024 VS 2031
Figure 3. API Features
Figure 4. Preparation Features
Figure 5. Global Oligonucleotide Drug CDMO Services Market Share by Application: 2024 VS 2031
Figure 6. SME Pharmaceutical Company
Figure 7. Large Pharmaceutical Company
Figure 8. Oligonucleotide Drug CDMO Services Report Years Considered
Figure 9. Global Oligonucleotide Drug CDMO Services Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 10. Global Oligonucleotide Drug CDMO Services Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Region: 2020 VS 2024
Figure 12. North America Oligonucleotide Drug CDMO Services Revenue (US$ Million) Growth Rate (2020-2031)
Figure 13. Europe Oligonucleotide Drug CDMO Services Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. Asia-Pacific Oligonucleotide Drug CDMO Services Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Latin America Oligonucleotide Drug CDMO Services Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Middle East & Africa Oligonucleotide Drug CDMO Services Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Global Oligonucleotide Drug CDMO Services Market Share by Players in 2024
Figure 18. Global Top Oligonucleotide Drug CDMO Services Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Drug CDMO Services as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Oligonucleotide Drug CDMO Services Revenue in 2024
Figure 20. North America Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
Figure 21. North America Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
Figure 22. Europe Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
Figure 23. Europe Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
Figure 24. Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
Figure 25. Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
Figure 26. Latin America Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
Figure 27. Latin America Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
Figure 28. Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Type (2020-2025)
Figure 29. Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Application (2020-2025)
Figure 30. Bachem Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 31. WuXi TIDES Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 32. Ajinomoto Co Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 33. Waters Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 34. AGC Biologics Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 35. Merck KGaA Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 36. EUROAPI Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 37. CordenPharma Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 38. Cytiva Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 39. TriLink BioTechnologies Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 40. Medicilon Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 41. General Biol Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 42. BioSpring Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 43. Bio-Synthesis Inc Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 44. Aurisco Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 45. Suzhou Olipharma Co.,Ltd Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 46. Porton Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 47. RIBOPharm Revenue Growth Rate in Oligonucleotide Drug CDMO Services Business (2020-2025)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which companies rank high in the global Oligonucleotide Drug CDMO Services market?
The top companies in the global Oligonucleotide Drug CDMO Services market are Bachem、WuXi TIDES、Ajinomoto Co.
Related Reports
Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 146
USD 4900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 107
USD 4250.00
(Single User License)
Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-08
Pages: 135
USD 3950.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2026
The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published Date: 2026-01-08
Pages: 122
USD 2900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published Date: 2025-08-05
Pages: 158
USD 4900.00
(Single User License)
Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published Date: 2025-03-12
Pages: 138
USD 3950.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2025
The global market for Oligonucleotide Drug CDMO Services was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published Date: 2025-03-12
Pages: 99
USD 2900.00
(Single User License)
Global and United States Oligonucleotide Drug CDMO Services Market Report & Forecast 2024-2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published Date: 2024-10-11
Pages: 127
USD 4350.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Research Report 2024
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published Date: 2024-10-11
Pages: 99
USD 2900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Insights, Forecast to 2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published Date: 2024-10-11
Pages: 152
USD 4900.00
(Single User License)
Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2032
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 146
USD 4900.00 (Single User License)Global Oligonucleotide Drug CDMO Services Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Oligonucleotide Drug CDMO Services market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 107
USD 4250.00 (Single User License)Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.
Published: 2026-01-08
Pages: 135
USD 3950.00 (Single User License)Global Oligonucleotide Drug CDMO Services Market Research Report 2026
The global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
Published: 2026-01-08
Pages: 122
USD 2900.00 (Single User License)Global Oligonucleotide Drug CDMO Services Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Oligonucleotide Drug CDMO Services market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Published: 2025-08-05
Pages: 158
USD 4900.00 (Single User License)Oligonucleotide Drug CDMO Services - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Oligonucleotide Drug CDMO Services was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.
Published: 2025-03-12
Pages: 138
USD 3950.00 (Single User License)Global Oligonucleotide Drug CDMO Services Market Research Report 2025
The global market for Oligonucleotide Drug CDMO Services was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Published: 2025-03-12
Pages: 99
USD 2900.00 (Single User License)Global and United States Oligonucleotide Drug CDMO Services Market Report & Forecast 2024-2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published: 2024-10-11
Pages: 127
USD 4350.00 (Single User License)Global Oligonucleotide Drug CDMO Services Market Research Report 2024
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published: 2024-10-11
Pages: 99
USD 2900.00 (Single User License)Global Oligonucleotide Drug CDMO Services Market Insights, Forecast to 2030
Oligonucleotide drug CDMO (Contract Development and Manufacturing Organization) Services refer to outsourcing solutions specifically provided to pharmaceutical companies involving the development, production and related services of oligonucleotide drugs. These services generally cover R&D services, production of clinical trial materials, commercial production, quality control and analysis, registration and compliance support, etc. Through these services, CDMO can help pharmaceutical companies reduce R&D and production costs, shorten time to market, and increase the success rate of products, allowing pharmaceutical companies to focus on their core business.
Published: 2024-10-11
Pages: 152
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4250.00
USD 6375.00
USD 8500.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now